9.13
-0.37 (-3.89%)
| Penutupan Terdahulu | 9.50 |
| Buka | 9.77 |
| Jumlah Dagangan | 7,547,222 |
| Purata Dagangan (3B) | 4,653,400 |
| Modal Pasaran | 1,501,319,936 |
| Harga / Jualan (P/S) | 2.52 |
| Harga / Buku (P/B) | 41.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | 38.14% |
| Margin Operasi (TTM) | 77.40% |
| EPS Cair (TTM) | 2.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 610.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 179.90% |
| Nisbah Semasa (MRQ) | 2.06 |
| Aliran Tunai Operasi (OCF TTM) | -189.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 61.88 M |
| Pulangan Atas Aset (ROA TTM) | 19.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Novavax, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.78% |
| % Dimiliki oleh Institusi | 57.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Shah Capital Management | 31 Mar 2026 | 14,845,097 |
| Sanofi | 31 Mar 2026 | 6,880,481 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |